Compare Glenmark Pharma with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs TORRENT PHARMA - Comparison Results

GLENMARK PHARMA     Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA TORRENT PHARMA GLENMARK PHARMA/
TORRENT PHARMA
 
P/E (TTM) x 14.6 38.4 38.0% View Chart
P/BV x 1.9 8.3 22.4% View Chart
Dividend Yield % 0.5 0.7 73.8%  

Financials

 GLENMARK PHARMA   TORRENT PHARMA
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-19
TORRENT PHARMA
Mar-19
GLENMARK PHARMA/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs7121,964 36.2%   
Low Rs4841,245 38.8%   
Sales per share (Unadj.) Rs349.6453.4 77.1%  
Earnings per share (Unadj.) Rs32.825.8 127.1%  
Cash flow per share (Unadj.) Rs44.362.3 71.2%  
Dividends per share (Unadj.) Rs2.0017.00 11.8%  
Dividend yield (eoy) %0.31.1 31.6%  
Book value per share (Unadj.) Rs198.6279.2 71.2%  
Shares outstanding (eoy) m282.17169.22 166.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.73.5 48.3%   
Avg P/E ratio x18.262.2 29.3%  
P/CF ratio (eoy) x13.525.8 52.3%  
Price / Book Value ratio x3.05.7 52.3%  
Dividend payout %6.165.9 9.3%   
Avg Mkt Cap Rs m168,625271,513 62.1%   
No. of employees `00012.013.6 88.5%   
Total wages/salary Rs m20,56114,038 146.5%   
Avg. sales/employee Rs Th8,196.05,642.6 145.3%   
Avg. wages/employee Rs Th1,708.11,032.4 165.5%   
Avg. net profit/employee Rs Th768.5320.9 239.5%   
INCOME DATA
Net Sales Rs m98,65576,728 128.6%  
Other income Rs m2,081571 364.8%   
Total revenues Rs m100,73677,299 130.3%   
Gross profit Rs m15,85819,831 80.0%  
Depreciation Rs m3,2596,177 52.8%   
Interest Rs m3,3465,038 66.4%   
Profit before tax Rs m11,3359,187 123.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1,672-3,570 -46.8%   
Tax Rs m3,7561,254 299.7%   
Profit after tax Rs m9,2504,363 212.0%  
Gross profit margin %16.125.8 62.2%  
Effective tax rate %33.113.6 242.9%   
Net profit margin %9.45.7 164.9%  
BALANCE SHEET DATA
Current assets Rs m66,96850,375 132.9%   
Current liabilities Rs m40,21151,653 77.8%   
Net working cap to sales %27.1-1.7 -1,628.6%  
Current ratio x1.71.0 170.8%  
Inventory Days Days8392 90.5%  
Debtors Days Days8168 118.9%  
Net fixed assets Rs m33,32283,648 39.8%   
Share capital Rs m282846 33.3%   
"Free" reserves Rs m55,77046,397 120.2%   
Net worth Rs m56,05247,244 118.6%   
Long term debt Rs m35,73839,129 91.3%   
Total assets Rs m132,888141,209 94.1%  
Interest coverage x4.42.8 155.4%   
Debt to equity ratio x0.60.8 77.0%  
Sales to assets ratio x0.70.5 136.6%   
Return on assets %9.56.7 142.4%  
Return on equity %16.59.2 178.7%  
Return on capital %17.812.3 144.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m62,99822,103 285.0%   
Fx outflow Rs m22,8595,522 414.0%   
Net fx Rs m40,14016,581 242.1%   
CASH FLOW
From Operations Rs m13,24217,981 73.6%  
From Investments Rs m-6,990-2,413 289.7%  
From Financial Activity Rs m-7,387-13,145 56.2%  
Net Cashflow Rs m-2,9712,380 -124.8%  

Share Holding

Indian Promoters % 48.3 71.5 67.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 7.0 98.3%  
FIIs % 34.4 12.6 273.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 8.8 119.3%  
Shareholders   56,727 26,511 214.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   BIOCON   CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  FDC LTD.  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Rallies 1,000 Points; Bajaj Finance, Titan & Tata Steel Surge Over 7%(12:30 pm)

Share markets in India are presently trading on a strong note after the government eased curbs on most economic activities, even as the lockdown in containment zones was extended till June 30.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 2.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, TORRENT PHARMA has posted a net profit of Rs 3 bn (up 2.0% YoY). Sales on the other hand came in at Rs 20 bn (down 4.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 36.3% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 36.3% YoY). Sales on the other hand came in at Rs 20 bn (up 5.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 5, 2019 | Updated on Sep 5, 2019

Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

6 Charts Showing the State of Indian Financial Markets in 2020(Sector Info)

May 26, 2020

Six charts showing how Indian financial markets have performed in 2020 so far...

This 'Essential Product' Smallcap is a Must Have for a 'Covid-19' Immune Portfolio(Profit Hunter)

May 19, 2020

This smallcap company needs no stimulus measures to do well in the long term.

What the RBI's Rate Cut Means for Options Traders(Fast Profits Daily)

May 25, 2020

The RBI governor has cut the repo rate to 4%. What does this mean for options traders? Find out in this video.

Which Stocks Should You Buy, Sell, and Hold in the Market Today?(Profit Hunter)

May 21, 2020

The coronavirus led uncertainty refuses to go away from the markets. Here's what retail investors should do with their stocks...

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Jun 1, 2020 01:09 PM

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 5-YR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS